Skip to main content

Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighs

Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.